Osteoporosis and vertebral fractures in ankylosing spondylitis

Current Opinion in Rheumatology

Volumn 25, Issue 4, 2013, Pages 509-516

  Davey Ranasinghe, Nicole ^a   Deodhar, Atul ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

ankylosing spondylitis; osteoimmunology; osteoporosis; vertebral fractures

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; SYNAPSIN I; TESTOSTERONE; VITAMIN D;

ANKYLOSING SPONDYLITIS; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPINE; SPINE FRACTURE; TRABECULAR BONE; WNT SIGNALING PATHWAY;

BONE DENSITY CONSERVATION AGENTS; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PREVALENCE; SPINAL FRACTURES; SPONDYLITIS, ANKYLOSING;

EID: 84879885595     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283620777     Document Type: Review

References (50)

1. Montala N, Juanola X, Collantes E. Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol 2011; 38:893-897.
2. Jun JB, Joo KB, Her MY, et al. Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 2006; 33:1637-1641.
3. Vosse D, de Vlam K. Osteoporosis in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (4 Suppl 55):S62-S67.
4. Karberg K, Zochling J, Sieper J, et al. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005; 32:1290-1298. (Pubitemid 40995385)
5. Schett G, Rudwaleit M. Can we stop progression of ankylosing spondylitis? Best Pract Res Clin Rheumatol 2010; 24:363-371.
6. Klingberg E, Lorentzon M, Mellstrom D, et al. Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and peripheral skeleton. J Rheumatol 2012; 39:1987-1995.
7. Ghozlani I, Ghazi M, Nouijai A, et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009; 44:772-776.
8. Korkosz M, Gasowski J, Grzanka P, et al. Baseline new bone formation does not predict bone loss in ankylosing spondylitis as assessed by quantitative computed tomography (QCT): 10-year follow-up. BMC Musculoskelet Disord 2011; 12:121.
9. van der Weijden MA, Claushuis TA, Nazari T, et al. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 2012; 31:1529-1535.
10. Vosse D, Feldtkeller E, Erlendsson J, et al. Clinical vertebral fractures in patients with ankylosing spondylitis. J Rheumatol 2004; 31:1981-1985. (Pubitemid 39336723)
11. Cooper C, Carbone L, Michet CJ, et al. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 1994; 21:1877-1882. (Pubitemid 24312651)
12. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007; 19:335-339. (Pubitemid 46884187)
13. Robinson Y, Sanden B, Olerud C. Increased occurrence of spinal fractures related to ankylosing spondylitis: a prospective 22-year cohort study in 17 764 patients from a national registry in Sweden. Patient Saf Surg 2013; 7:2.
14. Klingberg E, Lorentzon M, Mellstrom D, et al. Osteoporosis in ankylosing spondylitis: prevalence, risk factors and methods of assessment. Arthritis Res Ther 2012; 14:R108.
15. Mitra D, Elvins DM, Speden DJ, Collins AJ. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology (Oxford) 2000; 39:85-89. (Pubitemid 30095412)
16. Feldtkeller E, Khan MA, van der Heijder D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23:61-66. (Pubitemid 36384722)
17. Arends S, Spoorenberg A, Bruyn GA, et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 2011; 22:1431-1439.
18. Chaudhary SB, Hullinger H, Vives MJ. Management of acute spinal fractures in ankylosing spondylitis. ISRN Rheumatol 2011; 2011:150484.
19. Bessant R, Harris C, Keat A. Audit of the diagnosis, assessment, and treatment of osteoporosis in patients with ankylosing spondylitis. J Rheumatol 2003; 30:779-782. (Pubitemid 36402773)
20. Bessant R, Keat A. How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 2002; 29:1511-1519. (Pubitemid 34755621)
21. Lange U, Kluge A, Strunk J, et al. Ankylosing spondylitis and bone mineral density: what is the ideal tool for measurement? Rheumatol Int 2005; 26:115-120. (Pubitemid 41779819)
22. Vasdev V, Bhakuni D, Garg MK, et al. Bone mineral density in young males with ankylosing spondylitis. Int J Rheum Dis 2011; 14:68-73.
23. Gilgil E, Kacar C, Tuncer T, Butun B. The association of syndesmophytes with vertebral bone mineral density in patients with ankylosing spondylitis. J Rheumatol 2005; 32:292-294. (Pubitemid 40209128)
24. Speden DJ, Calin AI, Ring FJ, Bhalla AK. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 2002; 29:516-521. (Pubitemid 34202821)
25. Jansen TL, Aarts MH, Zanen S, Bruyn GA. Risk assessment for osteoporosis by quantitative ultrasound of the heel in ankylosing spondylitis. Clin Exp Rheumatol 2003; 21:599-604. (Pubitemid 37236453)
26. Rosenbaum J, Chandran V. Management of comorbidities in ankylosing spondylitis. Am J Med Sci 2012; 343:364-366.
27. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012; 11:234-250.
28. Taylan A, Sari I, Akinci B, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 2012; 13:191
29. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60:3257-3262.
30. Daoussis D, Andonopoulos AP. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 2011; 41:170-177.
31. Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010; 69:592-597.
32. Schett G, Sieper J. Inflammation and repair mechanisms. Clin Exp Rheumatol 2009; 27 (4 Suppl 55):S33-S35.
33. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009; 11:210.
34. Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 2011; 63:2215-2225.
35. Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013; 72:23-28.
36. Schett G. Independent development of inflammation and new bone formation in ankylosing spondylitis. Arthritis Rheum 2012; DOI: 10.1002/art.34441. [Epub ahead of print].
37. Maksymowych WP, Elewaut D, Schett G. Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum 2012; 64:1713-1719.
38. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondylo- Arthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 (Suppl 2):ii1-44.
39. Maksymowych WP, Inman RD, Gladman D, et al. Canadian Rheumatology Association Consensus on the use of antitumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003; 30:1356-1363. (Pubitemid 36666368)
40. Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol 2007; 19:340-345. (Pubitemid 46884188)
41. Haibel H, Braun J, Maksymowych WP. Bisphosphonates: targeting bone in the treatment of spondyloarthritis. Clin Exp Rheumatol 2002; 20 (6 Suppl 28): S162-S166.
42. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67:511-517. (Pubitemid 351498433)
43. Visvanathan S, Van Der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:175-182.
44. Einsiedel T, Schmelz A, Arand M, et al. Injuries of the cervical spine in patients with ankylosing spondylitis: experience at two trauma centers. J Neurosurg Spine 2006; 5:33-45. (Pubitemid 47325412)
45. May PJ, Raunest J, Herdmann J, Jonas M. Treatment of spinal fracture in ankylosing spondylitis. Unfallchirurg 2002; 105:165-169. (Pubitemid 36062312)
46. Thumbikat P, Hariharan RP, Ravichandran G, et al. Spinal cord injury in patients with ankylosing spondylitis: a 10-year review. Spine (Phila Pa 1976) 2007; 32:2989-2995. (Pubitemid 350307282)
47. Vosse D, Landewe R, van der Heijde D, et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009; 68:1839-1842.
48. Geusens P, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res Ther 2011; 13:242.
49. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 2011; 22:421-433.
50. Mermerci Baskan B, Pekin Dogan Y, Sivas F, et al. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int 2010; 30:375-381.